<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317821</url>
  </required_header>
  <id_info>
    <org_study_id>dAVF-Phil Registry</org_study_id>
    <nct_id>NCT03317821</nct_id>
  </id_info>
  <brief_title>PHIL Evaluation in the Endovascular Treatment of Intracranial Dural AVF</brief_title>
  <official_title>PHIL Evaluation in the Endovascular Treatment of Intracranial Dural AVF, a European Multi-center, Observational, Prospective, Single Arm and Open Label Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microvention-Terumo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinSearch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Microvention-Terumo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the safety and efficacy of the PHIL®
      liquid in endovascular treatment of dural arteriovenous fistula.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an European multi-center observational study. Treatments and follow-up visits will be
      done as per standard of care.

      The objective of this study is to evaluate the efficacy and safety of the PHIL® device in the
      treatment of intracranial dural ArterioVenous Fistula (dAVF). The PHIL® device, a
      non-adhesive liquid embolic agent, has been CE marked since July 2014. It is intended for use
      in the embolization of lesions in the peripheral and neurovasculature, including
      arteriovenous malformations and hypervascular tumors.

      All patients with an intracranial dAVF that has not been previously treated and will be
      treated by embolization with PHIL® are eligible for this study. A maximum of 60 patients will
      be enrolled in this study in 16 European Institutions.

      The expected approximate study duration is 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Number of adverse events and assessment of neurological status at 1 month after each embolization</measure>
    <time_frame>1 month</time_frame>
    <description>Neurological assessment by mRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of cure rate and of clinical course of the patient (stable /improvement /deteriorated)</measure>
    <time_frame>3-6 months after last embolization</time_frame>
    <description>Cure rate assessment by Angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and assessment of neurological status</measure>
    <time_frame>3-6 months after last embolization</time_frame>
    <description>Neurological assessment by mRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the quality of life of the patient and changes in patients symptoms</measure>
    <time_frame>3-6 months after last embolization</time_frame>
    <description>Assessed by Quality of Life Questionnaire EQ 5D</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dural Arteriovenous Fistula</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Any patients having an untreated dural arteriovenous fistula requiring treatment will be
        screened by the investigational sites. Those eligible to be treated with PHIL® will be
        enrolled after having dated and signed an informed consent form as per appropriate
        regulation in the participating country.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient or patient's legally authorized representative has received information about
             data collection and has signed and dated an Informed Consent Form

          2. Patient has an intracranial dAVF that can be treated by embolization with PHIL® used
             with or without other embolization products except other non-adhesive liquid embolic
             agents (i.e. Squid, Onyx).

          3. Patient is at least 18 years of age.

        Exclusion Criteria:

          1. Patient has multiple dAVFs to be treated.

          2. Patient participates in a study evaluating another medical device, procedure, or
             medication during the course of dAVF treatment and follow-up per the study protocol.

          3. Patient does not give consent to the collection and processing of data required for
             centralized monitoring

        3. Any condition that could prevent patient follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andres Gamez</last_name>
    <phone>0033661451518</phone>
    <email>andres.gamez@microvention.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Boyer</last_name>
    <phone>003367013998</phone>
    <email>patricia.boyer@microvention.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet University</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Markus Holtmannspötter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pellgrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florent Maire</last_name>
      <email>florent.maire@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Barreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent Spelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Tarnaud</last_name>
      <email>neuro-radiologie@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Charbel Mounayer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lopes Lucia</last_name>
      <email>llopes@for.paris</email>
    </contact>
    <investigator>
      <last_name>Michel Piotin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne-Christine Januel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario General de Catalunya</name>
      <address>
        <city>Barcelona</city>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Leopoldo Guimaraens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Senora del Rosario</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alfredo Casasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mariano Espinosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Romance Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alejandro Gonzales Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhus Umea</name>
      <address>
        <city>Umeå</city>
        <zip>90746</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mats Cronqvist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ljbubisa Borota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Saleh Lamin, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Mark Keston, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lesley Honeyfield</last_name>
      <email>lesley.honeyfield@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Lyriakos Lobotesisi, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Central Nervous System Vascular Malformations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

